nivolumab,ipilimumab
bms
['niche2']
importantly, #niche2 will be considered a success from the safety and feasibility endpoint (but we all want to see the 3-year survival too coming at a future ) #esmo22 
#MedicalOncologist tweeting on #immunotherapy, #drugdevelopment, #COVID19 & #HealthEcon. #NCI #CancerMoonshot Adult Immunotherapy Co-Chair. Tweets are mine.